comparemela.com

Latest Breaking News On - Professor of biological drug development - Page 1 : comparemela.com

New approach could lead to quicker generation of effective, personalized cancer vaccines

Scientists have created a pipeline for identifying, prioritizing and evaluating potential tumor antigens for the fast generation of cancer vaccines, according to a report published today in eLife.

Eteläuomen läiVincenzo cerulloSara feolaEmily hendersonUniversity of helsinkiEuropean research councilImmunovirotherapy lab ivtlabProfessor of biological drug developmentFirst authorPostdoctoral researcherBiological drug developmentImmune response

Rapid peptide discovery and plug-and-play technology could make personalised cancer vaccines reality | For the press

A novel prioritisation pipeline and ‘plug-and-play’ vaccine technology opens up the possibility of rapidly generating tailored cancer vaccines for clinical use.

Eteläuomen läiVincenzo cerulloSara feolaUniversity of helsinkiEuropean research councilImmunovirotherapy lab ivtlabProfessor of biological drug developmentPostdoctoral researcherBiological drug development

Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment

/PRNewswire/ Valo Therapeutics Oy (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced.

Eteläuomen läiSari pesonenVincenzo cerulloMatthew vaughanValo pepticradPaul highamUniversity of helsinkiHelsinki innovation services ltdHead of the drug research programGroup leaderScius communications for valo txProfessor of biological drug developmentBiological drug developmentDrug research programInnovation services ltdProfessor vincenzo cerullo

Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment

/PRNewswire/ Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced.

Eteläuomen läiSari pesonenVincenzo cerulloValotx pepticradMatthew vaughanValo pepticradPaul highamScius communications for valotxUniversity of helsinkiHelsinki innovation services ltdHead of the drug research programGroup leaderProfessor of biological drug developmentBiological drug developmentDrug research programInnovation services ltd

Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment

/PRNewswire/ Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced.

Eteläuomen läiSari pesonenVincenzo cerulloValotx pepticradMatthew vaughanValo pepticradPaul highamScius communications for valotxUniversity of helsinkiHelsinki innovation services ltdHead of the drug research programGroup leaderProfessor of biological drug developmentBiological drug developmentDrug research programInnovation services ltd

vimarsana © 2020. All Rights Reserved.